Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 5 stocks made the list for top value stocks in the Biotechnology & Medical Research industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.

Why Focus on Undervalued Biotechnology & Medical Research Stocks?

Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.

AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

What Goes Into AAII’s Value Grade?

Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.

Click the button below to learn more about A+ Investor and subscribe today.

5 Undervalued Biotechnology & Medical Research Stocks

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 5 undervalued stocks in the Biotechnology & Medical Research industry for Tuesday, August 27, 2024. Let’s take a closer look at their individual scores to see how they measure up against each other and the Biotechnology & Medical Research industry median.

The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.

The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)

Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).

As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.

Bluejay Diagnostics Inc’s Value Grade

Value Grade:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Bluejay Diagnostics Inc has a Value Score of 76, which is considered to be undervalued.

Now, let’s assess Bluejay Diagnostics Inc’s EV/EBITDA ratio, also known as enterprise multiple. At 0.9, when compared to the industry median of 1.0, the company may be considered undervalued in relation to its peers. Value investors could use the enterprise multiple to identify stocks that are considered overvalued or undervalued relative to their industry.

Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. Bluejay Diagnostics Inc’s shareholder yield is lower than its industry median ratio of (17.51%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.

As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. Bluejay Diagnostics Inc’s price-to-book ratio is lower than its industry median ratio of 2.11. This could make Bluejay Diagnostics Inc more attractive to investors looking for a new addition to their portfolio.

Bright Minds Biosciences Inc’s Value Grade

Value Grade:

Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Bright Minds Biosciences Inc has a Value Score of 69, which is considered to be undervalued.

Bright Minds Biosciences Inc’s price-to-book ratio is higher than its peers. This could make Bright Minds Biosciences Inc less attractive for value investors when compared to the industry median at 2.11.

You can read more about Bright Minds Biosciences Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

ENDRA Life Sciences Inc’s Value Grade

Value Grade:

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

ENDRA Life Sciences Inc has a Value Score of 76, which is considered to be undervalued.

ENDRA Life Sciences Inc’s price-to-book ratio is higher than its peers. This could make ENDRA Life Sciences Inc less attractive for value investors when compared to the industry median at 2.11.

You can read more about ENDRA Life Sciences Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

SQZ Biotechnologies Co’s Value Grade

Value Grade:

SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

SQZ Biotechnologies Co has a Value Score of 88, which is considered to be undervalued.

SQZ Biotechnologies Co’s price-to-book ratio is higher than its peers. This could make SQZ Biotechnologies Co less attractive for value investors when compared to the industry median at 2.11.

You can read more about SQZ Biotechnologies Co’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Protara Therapeutics Inc’s Value Grade

Value Grade:

Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Protara Therapeutics Inc has a Value Score of 73, which is considered to be undervalued.

Protara Therapeutics Inc’s price-to-book ratio is higher than its peers. This could make Protara Therapeutics Inc less attractive for value investors when compared to the industry median at 2.11.

You can read more about Protara Therapeutics Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Other Biotechnology & Medical Research Stock Grades

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.

Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Biotechnology & Medical Research stocks as well as other industrys.

Choosing Which of the 5 Best Biotechnology & Medical Research Stocks Is Right for You

Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.

• Bluejay Diagnostics Inc stock has a Value Grade of B.
• Bright Minds Biosciences Inc stock has a Value Grade of B.
• ENDRA Life Sciences Inc stock has a Value Grade of B.
• SQZ Biotechnologies Co stock has a Value Grade of A.
• Protara Therapeutics Inc stock has a Value Grade of B.

Now that you have a bit more background about each of the 5 undervalued stocks in the Biotechnology & Medical Research industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.

We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.

A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

Additional Resources About Biotechnology & Medical Research Stocks

Want to learn more about Biotechnology & Medical Research stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.

• 5 Undervalued Biotechnology & Medical Research Stocks for Tuesday, August 27
• 3 Undervalued Biotechnology & Medical Research Stocks for Monday, August 26
• Which Is a Better Investment, Agios Pharmaceuticals Inc or Janux Therapeutics Inc Stock?
• Which Is a Better Investment, Arrowhead Pharmaceuticals Inc or Janux Therapeutics Inc Stock?

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.